Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023GlobeNewsWire • 04/10/23
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease DementiaGlobeNewsWire • 03/30/23
Anavex: Many Questions Answered, A Few Still Left, But Things Are Progressing WellSeeking Alpha • 03/08/23
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 270.28% as Wall Street Analysts Expect?Zacks Investment Research • 02/15/23
Anavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDASeeking Alpha • 02/09/23
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical TrialGlobeNewsWire • 02/02/23
Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi ApprovedSeeking Alpha • 01/30/23
How Well Does Anavex's New Alzheimer's Drug Compare Against Biogen's New Drug?Seeking Alpha • 12/21/22
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer's TrialGlobeNewsWire • 12/14/22
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/12/22